FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126483794> ?p ?o ?g. }

• W3126483794 endingPage "58" @default.
• W3126483794 startingPage "47" @default.
• W3126483794 abstract "Abstract Globally, prostate cancer (PC) is a leading cause of death in men. Although androgen deprivation therapy (ADT) is the cornerstone of treatment for the disease, most patients eventually develop castration‐resistant PC (CRPC). Patients with non‐metastatic (nm) CRPC, the earliest clinical manifestation of castration resistance, are at risk of progressing to metastatic CRPC, which is associated with reduced life expectancy and poor quality of life. The nmCRPC treatment landscape has recently been transformed by the approval of three next‐generation oral androgen receptor (AR) inhibitors: apalutamide, enzalutamide and darolutamide. This review addresses available new treatment options for nmCRPC that target the AR, considering the effects of adverse event (AE) profiles and drug‐drug interactions (DDIs) when tailoring patient‐centric treatment to individual need, and discussing management strategies and nursing interventions for patients who experience drug‐related AEs. While no head‐to‐head comparisons of apalutamide, enzalutamide and darolutamide have been conducted to date, all three drugs have demonstrated comparable efficacy and maintained quality of life in phase III clinical trials, with differing AE profiles. The three treatments also demonstrate different potential for DDIs with other common medications that may be taken simultaneously. With the availability of new AR‐targeted options for nmCRPC, oncology nurses play a crucial role in the decision‐making process, educating and supporting patients on managing their PC, and ensuring that they receive the most appropriate treatment. As patients with nmCRPC are largely asymptomatic from their disease (with the exception of urinary/erectile symptoms), maintaining quality of life becomes a major objective when prescribing pharmacotherapy. Therefore, weighing treatment efficacy against the respective drug safety profile and examining the potential for adverse drug interactions with concomitant medications are important clinical considerations. Oncology nurses educate patients on potential treatment‐emergent AEs and their management and serve as advocates to ensure that patients receive optimal care based on their individual therapeutic requirements. They also provide information on available auxiliary services for patients and caregivers. This article provides an overview for the oncology nurse of the efficacy, safety, quality of life and DDI potential of these new AR‐targeted therapies in the nmCRPC setting, highlighting considerations for tailoring patient‐centric treatment to individual need. The importance of the oncology nurse in managing adverse drug reactions associated with ADT and AR inhibitors is highlighted and recommendations provided." @default.
• W3126483794 created "2021-02-15" @default.
• W3126483794 creator A5001088000 @default.
• W3126483794 creator A5017925159 @default.
• W3126483794 creator A5052884921 @default.
• W3126483794 creator A5060507085 @default.
• W3126483794 creator A5088518998 @default.
• W3126483794 date "2021-02-01" @default.
• W3126483794 modified "2023-10-16" @default.
• W3126483794 title "New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective" @default.
• W3126483794 cites W1844376808 @default.
• W3126483794 cites W1962221950 @default.
• W3126483794 cites W1968757604 @default.
• W3126483794 cites W1970345836 @default.
• W3126483794 cites W2019136566 @default.
• W3126483794 cites W2024652548 @default.
• W3126483794 cites W2026922854 @default.
• W3126483794 cites W2030521036 @default.
• W3126483794 cites W2042798052 @default.
• W3126483794 cites W2054203733 @default.
• W3126483794 cites W2105695629 @default.
• W3126483794 cites W2141569270 @default.
• W3126483794 cites W2155877563 @default.
• W3126483794 cites W2208340908 @default.
• W3126483794 cites W2261870911 @default.
• W3126483794 cites W2345887990 @default.
• W3126483794 cites W2439742409 @default.
• W3126483794 cites W2576656535 @default.
• W3126483794 cites W2590151349 @default.
• W3126483794 cites W2592479438 @default.
• W3126483794 cites W2594525893 @default.
• W3126483794 cites W2620522696 @default.
• W3126483794 cites W2755839016 @default.
• W3126483794 cites W2792086148 @default.
• W3126483794 cites W2793932506 @default.
• W3126483794 cites W2805742553 @default.
• W3126483794 cites W2810806599 @default.
• W3126483794 cites W2884125535 @default.
• W3126483794 cites W2885695264 @default.
• W3126483794 cites W2891576771 @default.
• W3126483794 cites W2895926103 @default.
• W3126483794 cites W2901733143 @default.
• W3126483794 cites W2911465702 @default.
• W3126483794 cites W2913767564 @default.
• W3126483794 cites W2915594591 @default.
• W3126483794 cites W2922403236 @default.
• W3126483794 cites W2925184412 @default.
• W3126483794 cites W2947670262 @default.
• W3126483794 cites W2978713040 @default.
• W3126483794 cites W3007420402 @default.
• W3126483794 cites W3011518560 @default.
• W3126483794 cites W3018168093 @default.
• W3126483794 cites W3018908320 @default.
• W3126483794 cites W3031020438 @default.
• W3126483794 cites W3083310601 @default.
• W3126483794 cites W3084238852 @default.
• W3126483794 doi "https://doi.org/10.1111/ijun.12263" @default.
• W3126483794 hasPublicationYear "2021" @default.
• W3126483794 type Work @default.
• W3126483794 sameAs 3126483794 @default.
• W3126483794 citedByCount "0" @default.
• W3126483794 crossrefType "journal-article" @default.
• W3126483794 hasAuthorship W3126483794A5001088000 @default.
• W3126483794 hasAuthorship W3126483794A5017925159 @default.
• W3126483794 hasAuthorship W3126483794A5052884921 @default.
• W3126483794 hasAuthorship W3126483794A5060507085 @default.
• W3126483794 hasAuthorship W3126483794A5088518998 @default.
• W3126483794 hasBestOaLocation W31264837941 @default.
• W3126483794 hasConcept C121608353 @default.
• W3126483794 hasConcept C126322002 @default.
• W3126483794 hasConcept C143998085 @default.
• W3126483794 hasConcept C159110408 @default.
• W3126483794 hasConcept C177713679 @default.
• W3126483794 hasConcept C197934379 @default.
• W3126483794 hasConcept C2776551883 @default.
• W3126483794 hasConcept C2777899217 @default.
• W3126483794 hasConcept C2778313021 @default.
• W3126483794 hasConcept C2779134260 @default.
• W3126483794 hasConcept C2779951463 @default.
• W3126483794 hasConcept C2780192828 @default.
• W3126483794 hasConcept C36434225 @default.
• W3126483794 hasConcept C535046627 @default.
• W3126483794 hasConcept C61367390 @default.
• W3126483794 hasConcept C71924100 @default.
• W3126483794 hasConceptScore W3126483794C121608353 @default.
• W3126483794 hasConceptScore W3126483794C126322002 @default.
• W3126483794 hasConceptScore W3126483794C143998085 @default.
• W3126483794 hasConceptScore W3126483794C159110408 @default.
• W3126483794 hasConceptScore W3126483794C177713679 @default.
• W3126483794 hasConceptScore W3126483794C197934379 @default.
• W3126483794 hasConceptScore W3126483794C2776551883 @default.
• W3126483794 hasConceptScore W3126483794C2777899217 @default.
• W3126483794 hasConceptScore W3126483794C2778313021 @default.
• W3126483794 hasConceptScore W3126483794C2779134260 @default.
• W3126483794 hasConceptScore W3126483794C2779951463 @default.
• W3126483794 hasConceptScore W3126483794C2780192828 @default.
• W3126483794 hasConceptScore W3126483794C36434225 @default.
• W3126483794 hasConceptScore W3126483794C535046627 @default.

• next